Back
United Therapeutics Corporation (UTHR)
BiotechnologyUTHR · NASDAQ NMS - GLOBAL MARKET · USD
New to investing? How to read this page →$554.34
−1.66%Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for education and research only — not financial advice.
Key metrics
EPS
$27.86
ROE
20.3%
Gross margin
86.6%
Debt/Equity
Revenue growth
-1.6%
P/B ratio
Beta
Forward P/E
United Therapeutics Corporation — company intelligence
Earnings surprises
Q1 2026$5.82 vs $7.01 est-16.9%
Q4 2025$7.70 vs $7.33 est+5.1%
Q3 2025$7.16 vs $7.33 est-2.3%
Q2 2025$6.41 vs $7.08 est-9.5%
Insider activity · 90 days
0 buys138 sellsnet -134,030 shares
ROTHBLATT MARTINE ASell 131 · Jul 6, 2026
ROTHBLATT MARTINE ASell 135 · Jul 6, 2026
ROTHBLATT MARTINE ASell 306 · Jul 6, 2026
Recent SEC filings
4 — Insider transaction reportJul 9, 2026
4 — Insider transaction reportJul 9, 2026
4 — Insider transaction reportJul 8, 2026
Latest news
RBC Capital Maintains Outperform on United Therapeutics, Raises Price Target to $704 — Benzinga · 3d ago
United Therapeutics: Trifecta Of 2026 Tyvaso Franchise Filings Makes It A Compelling Buy — SeekingAlpha · 4d ago
United Therapeutics Vs. Regencell Bioscience: I Choose Profits Over Promises — SeekingAlpha · 5d ago
UTHR Strengthens Regenerative Medicine Platform With Thymmune Deal — Yahoo · 1w ago
United Therapeutics Corporation Acquires Thymmune Therapeutics — Yahoo · 1w ago
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
About United Therapeutics Corporation
Weekly undervalued picks (like UTHR)
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.